Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis

Evgeny Izumchenko, David Sidransky

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations


With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding of EGFR regulation by MIG6 and reveals that MIG6 antagonizes tumor formation in mutant EGFR-driven lung adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)472-474
Number of pages3
JournalCancer discovery
Issue number5
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis'. Together they form a unique fingerprint.

Cite this